Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Hoberück

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
European Urology|October 30, 2025
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE RegistryMadeleine J Karpinski, Sebastian Hoberück, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE RegistryNika Guberina, Madeleine J Karpinski, Maja Guberina, et al.
European Urology|May 3, 2025
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry StudyMadeleine J Karpinski, Kambiz Rahbar, Martin Bögemann, et al.
The Lancet. Oncology|March 12, 2026
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort studyMadeleine J Karpinski, Caner Civan, Isabel Rauscher, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
European Urology|October 30, 2025
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE RegistryMadeleine J Karpinski, Sebastian Hoberück, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE RegistryNika Guberina, Madeleine J Karpinski, Maja Guberina, et al.
European Urology|May 3, 2025
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry StudyMadeleine J Karpinski, Kambiz Rahbar, Martin Bögemann, et al.
The Lancet. Oncology|March 12, 2026
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort studyMadeleine J Karpinski, Caner Civan, Isabel Rauscher, et al.
Pageof 4